Shares of Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 1,921.36 ($24.10) and traded as high as GBX 2,000 ($25.08). Hikma Pharmaceuticals shares last traded at GBX 1,991.27 ($24.98), with a volume of 387,164 shares traded.
Wall Street Analysts Forecast Growth
Separately, Berenberg Bank raised shares of Hikma Pharmaceuticals to a "buy" rating and boosted their target price for the stock from GBX 2,100 ($26.34) to GBX 2,400 ($30.10) in a research report on Monday, September 2nd.
Read Our Latest Report on Hikma Pharmaceuticals
Hikma Pharmaceuticals Trading Up 0.2 %
The company has a current ratio of 1.66, a quick ratio of 1.27 and a debt-to-equity ratio of 55.48. The stock has a 50-day simple moving average of GBX 1,913.50 and a 200 day simple moving average of GBX 1,921.46. The company has a market cap of £4.42 billion, a price-to-earnings ratio of 3,063.48, a PEG ratio of 2.38 and a beta of 0.41.
About Hikma Pharmaceuticals
(
Get Free Report)
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
Recommended Stories
Before you consider Hikma Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hikma Pharmaceuticals wasn't on the list.
While Hikma Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
